# Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy

> **NCT05263830** · — · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 240 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **OTHER:** Quantitative assay of GlypicanPC-3

## Key facts

- **NCT ID:** NCT05263830
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-08
- **Primary completion:** 2029-09-08
- **Final completion:** 2029-09-08
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263830, "Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05263830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*